BIOCRYST (BCRX) director Steven Frank granted 1,262 shares instead of $11,250 cash

Rhea-AI Filing Summary

Frank Steven reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC director Steven Frank received a stock award instead of cash compensation. He was granted 1,262 shares of common stock at a reference value of $8.91 per share on May 29, 2026, issued in lieu of a $11,250 quarterly board cash retainer. After this grant, he directly holds 20,165 shares of BIOCRYST common stock. This is a routine, compensation-related equity award rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Frank Steven

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,262	$8.91	$11K

Holdings After Transaction: Common Stock — 20,165 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock grant size: 1,262 shares Per-share value: $8.91 per share Cash retainer replaced: $11,250 +1 more

4 metrics

Stock grant size 1,262 shares Common Stock grant on May 29, 2026

Per-share value $8.91 per share Reference value for the stock grant

Cash retainer replaced $11,250 Quarterly board member cash retainer paid in stock

Shares held after grant 20,165 shares Total direct ownership after the transaction

Key Terms

Form 4, Common Stock, Grant, award, or other acquisition, Board Member retainer

4 terms

Form 4 regulatory

"Please analyze the following financial content according to the instructions above."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Board Member retainer financial

"in lieu of 100% of the quarterly cash Board Member retainer of $11,250."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frank Steven

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		1,262(1)	A	$8.91	20,165	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

	/s/ Alane P. Barnes, by power of attorney	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BIOCRYST (BCRX) director Steven Frank report in this Form 4?

Director Steven Frank reported receiving 1,262 shares of BIOCRYST common stock as a grant. The shares were issued as compensation, replacing his $11,250 quarterly board cash retainer, and increased his direct holdings to 20,165 shares after the transaction.

Was Steven Frank’s BIOCRYST (BCRX) Form 4 transaction an open-market stock purchase?

No, the transaction was not an open-market purchase. The Form 4 shows a grant of 1,262 shares coded as “A,” representing a stock award issued in lieu of a $11,250 quarterly cash retainer for his service as a board member.

How many BIOCRYST (BCRX) shares does Steven Frank hold after this Form 4 grant?

After the reported grant, Steven Frank directly holds 20,165 shares of BIOCRYST common stock. This total includes the 1,262-share award he received on May 29, 2026, as compensation in stock instead of his regular quarterly board cash retainer.

What does the $8.91 figure in the BIOCRYST (BCRX) Form 4 represent?

The $8.91 amount represents the per-share reference value used for the 1,262-share stock grant. The shares were issued as compensation in lieu of a $11,250 quarterly board cash retainer, rather than being bought or sold in the open market.

Why did BIOCRYST (BCRX) issue shares to Steven Frank instead of a cash retainer?

According to the Form 4 footnote, BIOCRYST issued shares to Steven Frank in lieu of 100% of his $11,250 quarterly cash board member retainer. This structure compensates him with equity, aligning part of his board compensation with the company’s stock performance.